65,437 trials
Pneumococcal Infections
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 — 24.9; 25.4; 22.3; 23.7 percentage of participants
Liver Cirrhosis · Portal Vein Thrombosis
Primary: Recanalization Rate — 20; 11 Participants
Alcohol Dependence · Alcohol Abuse · Substance Abuse
Primary: Mean Biphasic Alcohol Effects Scale (BAES) Scores — 27.5; 32.4; 23.0; 21.1 score on a scale
Refractory Multiple Myeloma · Smoldering Multiple Myeloma · Stage I Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 1600 cGy
Glioblastoma Multiforme
Primary: Objective Response — 22.5; 19.4; 11.3; 6.5 percentage of participants
Stroke, Acute
Primary: Myelin Basic Protein (MBP) Comparison Between the Two Groups Before and After Treatment — 0.42; 0.64; 0.41; 0.71 pg/ml
Cystic Fibrosis
Primary: Relative Change in Lung Function — 1.69; -1.95 percent change — p=0.0846
Solid Tumor · Colorectal Cancer
Primary: Percentage of Participants With Dose Limiting Toxicities (DLT) — 16.7; 0.0; 0.0; 14.3 percentage of participants
Obesity
Primary: Number of Participants With Weight Loss of 5% or More at 8 Weeks — 7; 7 Participants
Stress Urinary Incontinence
Primary: Number of Participants Who Remain Continent or Improved Following Treatment Through 3 Months Follow-up — 26 Participants
Body Fat Disorder
Primary: The Number of Device and/or Procedure-Related Adverse Events — 12 device or procedure-related AEs
Solid Tumors
Primary: Objective Response Rate (ORR) — 20.0; 30.0; 17.6; 0 percentage of participants
Cancer of the Pancreas
Primary: Change in Serum Adiponectin Level — 34.47; 29.77 μg/ml
Lip Augmentation
Primary: Assess Treatment With Restylane Kysse Using GAIS — 18; 38 Participants
Intracranial Aneurysm
Primary: Number of Participants Achieving Adequate Occlusion Immediate Post Procedure — 965 Participants